Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ligand Pharm
(NQ:
LGND
)
103.82
+0.20 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ligand Pharm
< Previous
1
2
3
Next >
Looking Into Ligand Pharmaceuticals's Recent Short Interest
August 16, 2024
Via
Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
After Monday's panicked global sell-off, markets have calmed down.
Via
Investor's Business Daily
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
August 06, 2024
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Via
Investor's Business Daily
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
July 30, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
June 28, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Ligand Pharmaceuticals's Earnings: A Preview
February 26, 2024
Via
Benzinga
Where Ligand Pharmaceuticals Stands With Analysts
September 19, 2023
Via
Benzinga
3 Magnificent Growth Stocks to Buy Hand Over Fist
May 22, 2024
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
May 20, 2024
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation.
Via
InvestorPlace
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
May 07, 2024
While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and...
Via
Talk Markets
7 Small-Cap Stocks for the Thinking Speculator
April 08, 2024
While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises.
Via
InvestorPlace
Analyst Expectations for Ligand Pharmaceuticals's Future
August 23, 2023
Via
Benzinga
Recap: Ligand Pharmaceuticals Q1 Earnings
May 04, 2023
Via
Benzinga
Ligand Pharmaceuticals Earnings Preview
February 21, 2023
Via
Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
December 23, 2022
Via
Benzinga
Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
February 27, 2024
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024.
Via
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
Via
Benzinga
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Via
Benzinga
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
September 19, 2023
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio...
Via
Benzinga
Why Are Novan Shares Nosediving Today?
July 17, 2023
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to
Via
Benzinga
3 Stocks That Smart Investors Should Be Flocking to Now
May 30, 2023
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors.
Via
InvestorPlace
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
May 16, 2023
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in
Via
Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Earnings Scheduled For February 22, 2023
February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.